Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027

Avalo Therapeutics, Inc.

Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.
Cash runway expected into at least 2027, funding Phase 2 LOTUS trial and expansion of AVTX-009 program.
As of Nov 8, 2024: 10,463,633 common shares outstanding; 24,895.92 Series C Preferred shares convertible into 24.9M common shares subject to ownership limits.
CEO states focus on hidradenitis suppurativa trial and identifying next inflammatory indication for AVTX-009.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.